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Abstract
Introduction Imported falciparum malaria is characterized by a
broad spectrum of potentially life-threatening complications that
may arise even after initiation of appropriate antimalarial drug
therapy. Hence, at Heidelberg University Hospital, all patients
with newly diagnosed falciparum malaria are initially treated in
the intermediate care unit (IMC) or intensive care unit (ICU). The
present study was undertaken to evaluate critically the benefit of
this strategy, which includes daily consultation with senior
specialists in tropical medicine.
Methods We conducted a retrospective cohort study at the 14-
bed combined IMC/ICU of a 1,685-bed university hospital. A
cohort of 122 patients with imported falciparum malaria
admitted from 1 January 1996 to 31 December 2003 was
included.
Results Thirty-four patients (27.9%) developed complications,
defined according to the current World Health Organization
classification. Most patients (80.3%) studied did not take the
recommended chemoprophylaxis against malaria. The majority
of patients (89.3% [n = 109]) could be adequately treated in the
IMC. Life-threatening complications requiring ICU support
occurred in 13 patients (10.7%). All complications were
successfully managed. Fifty-five patients (45.1%) fulfilling
recently published criteria for outpatient treatment had an
excellent therapeutic response and did not require ICU support.
Conclusion This retrospective evaluation demonstrated
favourable therapeutic results in hospitalized patients with
imported falciparum malaria. Both initial treatment in the medical
IMC/ICU and close collaboration between intensivists and
specialists in tropical medicine may improve disease outcome
among affected patients. Prospective studies are needed to
confirm these preliminary findings.
Introduction
With 10,000 to 12,000 diagnoses per year in the European
Union and 1,300 in the USA, imported malaria represents a
growing challenge for health practitioners in the Western
world [1,2]. In Germany, 800 to 1,000 cases of imported
malaria are registered each year, two-thirds of which are
caused by Plasmodium falciparum, the causative agent of fal-
ciparum malaria. Severe or complicated falciparum malaria is
characterized by a broad spectrum of life-threatening compli-
cations, in particular acute respiratory distress syndrome, renal
failure, circulatory shock and coma [3-8]. The course of the
disease is often precipitous, requiring rapid diagnosis and ini-
tiation of both specific antimalarial chemotherapy and appro-
priate supportive care [5,9]. Despite improvements in
intensive care management, the case fatality rate for compli-
cated malaria in the intensive care unit (ICU) is still high and
may reach up to 40% [9-12]. Unfavourable outcomes are at
least partly attributable to delayed initiation of appropriate
ICU = intensive care unit; IMC = intermediate care unit; WHO = World Health Organization.Critical Care    Vol 12 No 1    Schwake et al.
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supportive care [13-15]. Early initiation of intensified support-
ive care, including ICU admission, has therefore been pro-
posed by several investigators [2,10]. At the opposite end of
the spectrum, ambulatory treatment appears to be a safe
option in selected patients, as highlighted in recent publica-
tions [16,17]. Reliable criteria must be established so that
patients may be assigned to the appropriate management
strategy. At our institution, all patients with newly diagnosed
falciparum malaria are initially referred to a combined medical
intermediate care unit (IMC)/ISU, regardless of the presence
or absence of complications. The present study was designed
to evaluate critically the performance of this treatment strategy
with respect to complications and outcome.
Materials and methods
Study population and design
We evaluated all patients with imported falciparum malaria
admitted to the combined medical IMC/ICU of Heidelberg
University Hospital, Heidelberg, Germany, between 1 January
1996 and 31 December 2003, in a single-centre retrospective
observational study. Inclusion criteria were as follows: mini-
mum age 15 years and a newly diagnosed P. falciparum infec-
tion acquired in an endemic country and imported to Germany.
In all cases the diagnosis of falciparum malaria was based on
positive Giemsa-stained thin and thick blood smears, exam-
ined by experienced physicians of either the Department of
Laboratory Medicine or the Section of Clinical Tropical Medi-
cine. Ethics approval was obtained from the local ethics com-
mittee (Medical University Heidelberg).
Setting
The 14-bed medical ICU at Heidelberg University Hospital is
both a primary care and a tertiary referral centre for critically ill
patients. The unit is split into a seven-bed, fully equiped ICU
and a seven-bed intermediate care area (IMC). All patients are
treated by the same physician and nursing team.
Data collection
Patients' medical charts were reviewed retrospectively and the
following data were collected: demographic baseline data and
travel-related history (age, sex, region of travel, use of antima-
larial chemoprophylaxis), latency period (time from arrival in
Germany to presentation at hospital), signs and symptoms at
presentation, laboratory results, treatment, complications and
outcome data (mortality and length of stay both in the hospital
and in the ICU). Disease severity on admission to the ICU or
IMC was assessed by means of the Simplified Acute Physiol-
ogy Score II [18]. Chemoprophylaxis was considered inappro-
priate when it was either not taken at all or inadequate.
European travellers and tourists were considered nonimmune.
Patients who were born and grew up in malaria endemic areas
were defined as semi-immune.
Patient management
Since 1996 all patients with microscopically confirmed falci-
parum malaria have been directly referred to the medical IMC/
ICU. This treatment strategy was implemented after one fatal
course during the preceding year and was intended to pro-
mote optimal monitoring and treatment conditions. After the
initial assessment by the physician in charge, patients were
either transferred to the IMC area or to a regular, fully
equipped ICU bed. All patients received antimalarial drug ther-
apy immediately and were continuously monitored. Basic and
advanced supportive care measures provided to the patients
are summarized in Table 5 (see below). Additionally, urine out-
put was monitored hourly in critically ill patients and twice daily
in uncomplicated cases. Administration of blood components
was performed according to clinical judgement. Decisions
regarding transfusion of red blood cells were based on pub-
lished recommendations (fall of haemoglobin concentration by
20% within 24 hours or cardiac decompensation) [19]. None
of the patients developed severe anaemia (haemoglobin <5 g/
dl). Haemodialysis treatment was initiated in case of apparent
renal failure, as defined by World Health Organization (WHO)
criteria (Table 3; see below), despite adequate intravenous
fluid replacement. Daily consultations with senior specialists in
tropical medicine were held to discuss both antimalarial drug
therapy and supportive care. Discharge from the IMC/ICU was
based on consideration of the general status and clinical
course of the patient.
Drug treatment
Patients were treated with standard drug regimens, including
quinine and doxycycline, atovaquone/proguanil, and meflo-
quine, bearing in mind drug resistance patterns, pretreatment,
chemoprophylaxis taken and other individual factors (such as
individual contraindications to a specific drug). Patients with
complicated falciparum malaria received intravenous quinine
with a loading dose on ICU admission. Patients without com-
plications received intravenous quinine only if clinically indi-
cated. Dose adjustments in patients with acute renal failure or
hepatic dysfunction were performed as recommended by the
WHO guidelines [19,20]. None of the patients originated from
a multidrug-resistant region.
Definition of complications
Serious or complicated malaria was defined according to the
WHO criteria by the presence of one or more of the clinical
and laboratory manifestations enlisted in Table 3 (see below),
along with asexual forms of P. falciparum in peripheral blood
smear [9,19-22]. The presence of haemoglobinuria could not
be determined retrospectively. Serious complications requir-
ing immediate medical intervention were defined as those that
were life-threatening; they included circulatory shock, renal
failure, respiratory failure, acidosis, abnormal bleeding, severe
anaemia, coma or seizures, and hypoglycaemia.Available online http://ccforum.com/content/12/1/R22
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Data handling and statistical analysis
All patient data were documented on a spreadsheet (Excel
2000; Microsoft Corp, Redmond, WA, USA) and analyzed sta-
tistically using WinStat (R. Fitch Software, Staufen, Germany)
and SPSS 13.0 (SPSS Inc., Chicago, IL, USA) software.
Patients were categorized into groups on the basis of the pres-
ence or absence of complications. The distributions of contin-
uous variables were checked for normality using the
Kolmogorov–Smirnov test and, if appropriate, expressed as
mean ± standard deviation. For some laboratory data, logarith-
mic transformation was applied to achieve normality.
Continuous variables deviating from normality were presented
as median with interquartile range (25th to 75th percentile).
Unpaired Student's t-tests and Mann-Whitney U-test were
used to compare two groups. Candidate clinical and labora-
tory predictors of complications that were statistically signifi-
cant at the explorative level of 10% (P < 0.1) in the univariate
analysis were subjected to binary logistic regression to deter-
mine the independent contribution of each possible risk factor.
Receiver-operating characteristic curves and areas under the
respective curve (AUCs) were further calculated, and model fit
was assessed using the Hosmer-Lemeshow goodness-of-fit
statistic [23]. Categorical data were presented as absolute
numbers with associated percentages and evaluated using χ2
or Fisher's exact test, as appropriate. All tests were applied
two-tailed, and a P value of < 0.05 was considered to be sta-
tistically significant.
Results
Patient characteristics
Between January 1996 and December 2003, a total of 165
patients with malaria were admitted to the medical IMC/ICU.
Of these patients, 122 with P. falciparum malaria were
included in the present study. Thirty-three patients were
excluded because of infection with other Plasmodium spp. (P.
vivax, P. ovale and P. malariae) and ten patients because of
late transfer (>24 hours after diagnosis) or incomplete data
(Figure 1). A total of 116 patients were directly admitted to the
IMC/ICU via the Medical Emergency Department or the outpa-
tient clinic of the Section of Clinical Tropical Medicine. Six
patients were transferred to the ICU from referral hospitals
within 24 hours or less after diagnosis. The study population
was predominantly male. During the 8-year study period there
were no fatal cases of falciparum malaria. Table 1 lists patient
characteristics, demographic profiles, and signs and symp-
toms at the time of admission to the IMC/ICU. Patients with
complications were significantly older than patients without
complications. All but 15 of the 122 patients acquired P. falci-
parum malaria in sub-Saharan Africa. Other regions of travel
were Southern Africa, Asia and tropical South America,
accounting for eight cases, six cases and one case, respec-
tively. Chemoprophylaxis was inappropriate in 98 patients
(80.3%); it was not taken at all by 74 patients and inade-
quately by 24 patients.
Fifty-five patients (45.1%) fulfilled recently published criteria
for ambulatory treatment, namely parasitaemia under 1%,
absence of complications, age 16 years or older, and no vom-
iting [17]. In one of these patients hyperbilirubinaemia was
observed. None of these 55 patients required advanced sup-
portive care.
Laboratory results
Haematological and biochemical findings on admission are
shown in Table 2. Univariate logistic regression detected sig-
nificant differences between complicated and uncomplicated
malaria in 12 of the 16 parameters tested. Serum bilirubin, lac-
tate dehydrogenase and platelet concentrations exhibited the
greatest differences between groups. Significant differences
were also observed for initial and peak parasitaemia (P  <
0.0001); median parasitaemia on admission was 0.7% (inter-
quartile range 0.1% to 5%) for uncomplicated cases, and
21% (2.5% to 45%) for patients with complications defined
according to WHO criteria. Parasitaemia increased to a
median of 1.6% (0.2% to 5.7%) in patients without complica-
tions and 34% (11.5% to 72.1%) in complicated malaria.
Mild hyponatraemia (serum sodium 125 to 135 mmol/l) at
admission was a common finding and occurred in 77 patients
(63.1%). However, only one patient exhibited a serum sodium
concentration below 124 mmol/l. In addition, an increase in
aspartate aminotransferase to more than three times the upper
normal limit – usually regarded 'malaria hepatitis' – was docu-
mented in 27 patients (22.1%).
Complications
Table 3 shows the complications recorded on admission and
occurring during the IMC/ICU stay. Twenty-one of the 34
patients with a complicated course exhibited signs of compli-
cations at the time of admission to the IMC/ICU, whereas
another 13 patients without initial complications developed
them during their stay in the IMC/ICU. Hyperparasitaemia (>
5% parasitized erythrocytes) was present in eight patients on
admission and developed in five further patients during their
hospital stay. The corresponding numbers for hyperpara-
sitemia above 10% were five and one. Twenty-one patients
developed one complication, six patients two complications
and seven patients three or more complications. Life-threaten-
ing complications requiring ICU support were observed in
seven patients at admission and developed in six further
patients during the IMC/ICU stay. Three of the latter did not
exhibit any complications at the time of admission. The time
course of life-threatening complications is shown in Table 4.
Four of the five patients fulfilling the criteria for acute renal fail-
ure required haemodialysis. In one patient with renal failure,
haemodialysis could be avoided by careful intravenous rehy-
dration. Parasitaemia and markers of haemolysis (lactate dehy-
drogenase, aspartate aminotransferase and bilirubin) were
significantly higher in patients with acute renal failure than inCritical Care    Vol 12 No 1    Schwake et al.
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those with other complications, both on admission and during
hospital stay (data not shown).
Treatment
Quinine was given to 56 patients (45.9%), 44 of whom
received it intravenously. In 21 patients (17.2%) quinine was
given in combination with oral doxycyclin. Thirty-four patients
(27.9%) received mefloquine. Atovaquone/proguanil was
given in 42 cases (34.4%), as an exclusive treatment in 32
patients and to complete treatment after initial quinine therapy
in 10. A total of 270 blood units, including 78 packed red
blood cells, 82 thrombocyte concentrates and 110 fresh fro-
zen plasma, were transfused in 20 patients. Basic and
advanced supportive care measures for the 122 study
patients are listed in Table 5. Empirical antibiotic treatment
was given in four patients with either persistent shock or prob-
able pneumonia. All patients recovered completely and were
discharged from the hospital without residual sequelae.
Prognostic factors
Significant and nearly significant (P < 0.1) variables from the
univariate analysis were included in a multivariate binary logis-
tic regression model. Because of the small number of patients
with secondary acquisition of complications, we opted to
choose the need for advanced supportive care (Table 5) as
the variable of interest. Five patients needed immediate
advanced supportive care at the time of admission and were
therefore excluded from this analysis. A further nine patients
(including one patient with advanced supportive care) were
excluded because of missing laboratory data from chart
review. The Hosmer-Lemeshow goodness-of-fit χ2 statistic
was 9.548, with eight degrees of freedom (P = 0.298), which
indicates excellent calibration of the model. Binary logistic
regression demonstrated that haemoglobin and platelet levels
as well as serum sodium concentration at admission were
inversely associated with the need for advanced supportive
care (Table 6). The AUC for blood platelets was 0.837 (stand-
ard error 0.047; P < 0.001; 95% confidence interval 0.744 to
Table 1
Baseline characteristics at admission to the ICU
All malaria patients 
(n = 122 [100%])
Noncomplicated malaria 
(n = 88 [100%])
Complicated malaria 
(n = 34 [100%])
P
Demographics
Age (years; mean ± SD) 38.4 ± 11.1 37.1 ± 10.2 42 ± 12.8 0.049
Male sex (n [%]) 88 (72.1) 62 (70.5) 26 (76.5) 0.506
Return from Sub-Saharan Africa (n [%]) 107 (87.7) 76 (86,4) 31 (91.2) 0.350
Nonimmune patients (n [%]) 88 (72.1) 62 (70.5) 26 (76.5) 0.506
Compliant chemoprophylaxis users (n [%]) 24 (19.7) 17 (19.3) 7 (20.6) 0.874
Latency period (arrival-admission; days; median [IQR]) 10 (6–15) 10 (7–15) 8 (4–14) 0.778
Initial signs and symptoms
Fever (>37°C; n [%]) 118 (96.7) 84 (95.5) 34 (100) 0.265
Headache (n [%]) 71 (58.2) 57 (64.8) 14 (41.2) 0.018
Chills (n [%]) 43 (35.2) 31 (35.2) 12 (35.3) 0.994
Diarrhoea (n [%]) 46 (37.7) 29 (33) 17 (50) 0.082
Nausea (n [%]) 47 (38.5) 31 (35.2) 16 (47.1) 0.229
Vomiting (n [%]) 29 (23.8) 20 (22.7) 9 (26.5) 0.687
Jaundice (n [%]) 11 (9) 0 (0) 11 (32.4) 0.000
Confusion (n [%]) 5 (4.1) 0 (0) 5 (14.7) 0.001
Vertigo (n [%]) 25 (20.5) 14 (15.9) 11 (32.4) 0.044
Myalgias (n [%]) 47 (38.5) 34 (38.6) 13 (38.2) 0.967
Abdominal pain (n [%]) 10 (8.2) 6 (6.8) 4 (11.8) 0.893
Simplified Acute Physiology Score II (median [IQR]) 13 (9–20) 13 (9–17) 27 (17–36) 0.000
IMC/ICU length of stay (days; median [IQR]) 5 (3–6) 4 (2–5) 6 (5–8) 0.000
Hospital length of stay (days; median [IQR]) 6 (5–8) 5.5 (4–7) 8 (7–10) 0.000
ICU, intensive care unit; IMC, intermediate care unit; IQR, interquartile range (25th to 75th percentile); SD, standard deviation.Available online http://ccforum.com/content/12/1/R22
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0.929), suggesting good accuracy of blood platelets in pre-
dicting the need for advanced supportive care in the ICU. For
comparison, sodium levels had an AUC of 0.789 (standard
error 0.051; P < 0.001; 95% confidence interval 0.690 to
0.889) and blood haemoglobin concentration had an AUC of
0.686 (standard error 0.064; P = 0.007; 95% confidence
interval 0.561 to 0.811), indicating that these variables has
less discriminative power (see Figure 2).
Discussion
Because of the dynamics of P. falciparum infection, patients
may deteriorate within 24 hours despite initiation of adequate
antimalarial treatment [19,24]. Thus far, however, reliable cri-
teria for ICU admission as well as standardized protocols for
the supportive treatment of complications have not been
established [2,10]. This retrospective cohort study describes
clinical features and treatment of 122 patients with imported
falciparum malaria admitted to the combined medical IMC/ICU
of a university hospital over an 8-year period. In contrast to
conventional practice, all patients with newly diagnosed P. fal-
ciparum infection were initally referred to the IMC/ICU, regard-
less of the presence or absence of complications. Our results
clearly show that early IMC/ICU treatment of all patients with
imported falciparum malaria is associated with a favourable
clinical outcome; none of the patients died and all were dis-
charged from the hospital without sequelae.
Previous studies of the treatment of imported malaria in the
ICU have reported much higher mortality rates. In a study
reported in 2003 [2], a French group evaluated 188 patients
admitted to an ICU for treatment of imported falciparum
malaria over a 12-year period. In contrast to our patient cohort,
all patients included in that study suffered from complicated
malaria and their overall mortality was 5.3%. A few years earlier
the same authors described 50 patients with complicated fal-
ciparum malaria treated in a medical ICU over a 6-year period
[25]. The corresponding mortality rate was 14% in this analy-
sis, mostly due to refractory circulatory shock. In a survey from
Austria [10] seven out of 69 patients with falciparum malaria
were admitted to the medical ICU for treatment of complica-
tions; three patients died despite sophisticated ICU
management, corresponding to an ICU mortality rate of 40%.
In a recently published analysis from Germany [26], 21 out of
116 patients with falciparum malaria were treated in the ICU,
of whom two patients died.
In all of these studies patients were only transferred to the ICU
in case of serious complications or deterioration, despite
appropriate antimalarial drug therapy. This strategy, which
reflects usual clinical practice, has several pitfalls, however.
Doctors and nursing staff on regular (non-ICU) wards may
face problems in providing the 24-hour monitoring that is nec-
essary to detect arising complications rapidly. Furthermore,
Figure 1
Flow chart of patients included in the study Flow chart of patients included in the study. ICU = intensive care unit; IMC = intermediate care unit.Critical Care    Vol 12 No 1    Schwake et al.
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loss of information during ICU transfer may cause delayed and
suboptimal treatment. Our approach differs markedly from this
'traditional' treatment policy, mainly by providing a higher level
of initial observation and by shortening the response to
upcoming complications. Indeed, this strategy enabled us to
successfully manage all arising complications over an 8-year
period. We hypothesize that a number of potentially preventa-
tive measures in the IMC contributed to the low rate of major
complications in our patient cohort: intense monitoring, close
surveillance by doctors and nursing staff, and rapid medical
response to upcoming complications.
As shown by others, rapid correction of both hypovolaemia
and circulatory overload by means of intravenous hydration
and diuretic therapy is essential to prevent the development of
life-threatening complications, including circulatory shock,
acute renal failure and acute respiratory distress syndrome
[19]. Early transfusion of blood products (none of the patients
developed severe anaemia) might have further supported
these effects. Acute renal failure that is (as in our patient
cohort) typically associated with high parasitaemia and signif-
icant haemolysis have been shown to carry particular risk
[27,28]. Hence, in our patient group renal replacement ther-
apy was promptly initiated once signs of acute renal failure
were present and did not rapidly improve with intravenous
rehydration. This strategy is consistent with suggestions by
other authors and has been shown to be beneficial [27,29,30].
Our study raises additional concerns that must be addressed.
The data presented herein clearly show that initial IMC/ICU
admission does not completely prevent the development of
serious complications; life-threatening complications requiring
immediate intervention developed in six patients after initiation
of treatment in the IMC/ICU. Most importantly, half of these
patients did not have any complications at the time of admis-
sion. One explanation for this phenomenon is that side effects
of antimalarial drugs as well as nosocomial infections may
facilitate the development of serious complications [8,24]. In
two of the three patients mentioned above, severe hypogly-
caemia, probably due to quinine administration and the para-
sites' glucose demand, was the only complication observed
during the ICU stay. Another four patients exhibited clinical
signs of septicaemia requiring broad-spectrum antibiotic treat-
ment. These observations illustrate both the difficulties in pre-
dicting severe courses of the disease and the need to monitor
treatment complications.
Initial treatment of all patients with imported falciparum malaria
in the hospital setting continues to be the most common prac-
tice in Western countries [24]. However, results from two
recently published prospective observational studies have
Table 2
Laboratory findings at admission to the ICU
Parameter All malaria patients 
(n = 122 [100%])
Noncomplicated malaria 
(n = 88 [100%])
Complicated malaria 
(n = 34 [100%])
P Numbers of 
patients 
tested
Haemoglobin (g/dl; mean ± SD) 13.7 ± 2 14 ± 1.9 12.9 ± 2.3 0.007 122
Platelet count (× 109/l; mean ± SD) 89 ± 51 104 ± 49 50 ± 32 0.000 122
White blood cell count (× 109/l; mean ± SD) 5.4 ± 2.2 5.1 ± 2.0 6.1 ± 2.5 0.023 122
Plasma prothrombin time (%; mean ± SD) 78 ± 17 79 ± 16 73 ± 17 0.066 122
Serum sodium (mmol/l; mean ± SD) 134 ± 4.7 135 ± 4.2 131 ± 4.6 0.000 122
Serum potassium (mmol/l; mean ± SD) 3.9 ± 0.5 3.8 ± 0.4 3.9 ± 0.7 0.739 122
Serum glucose (mg/dl; mean ± SD) 119 ± 32 124 ± 38 117 ± 29 0.287 122
Total bilirubin (mg/dl; mean ± SD) 1.5 ± 1.8 0.9 ± 0.4 2.8 ± 2.7 0.000 98
C-reactive protein (mg/l; mean ± SD) 102 ± 63 82 ± 45 151 ± 73 0.000 113
Serum aspartate aminotransferase (U/l, median 
[IQR])
37 (27–72) 33 (26–59) 61 (35–88) 0.001 122
Serum alanine aminotransferase (U/l; mean ± SD) 60 ± 39 56 ± 36 72 ± 44 0.045 122
Serum creatinine (mg/dl; median [IQR]) 1.1 (0.9–1.3) 1 (0.9–1.2) 1.2 (1.1–1.8) 0.000 122
Serum urea (mg/dl [mean ± SD]) 40 ± 32 29 ± 11 67 ± 48 0.000 122
Serum alkaline phosphatase (U/l [mean ± SD]) 83 ± 36 81 ± 31 88 ± 46 0.457 96
γ-Glutamyl transferase (U/l; mean ± SD) 68 ± 89 60 ± 92 85 ± 79 0.213 99
Lactate dehydrogenase (U/l; mean ± SD) 333 ± 202 259 ± 81 524 ± 282 0.000 122
ICU, intensive care unit; IMC, intermediate care unit; IQR, interquartile range (25th to 75th percentile); SD, standard deviation.Available online http://ccforum.com/content/12/1/R22
Page 7 of 10
(page number not for citation purposes)
shown that outpatient treatment of uncomplicated falciparum
malaria in adults with low parasitaemia (< 1%) and without
vomiting can be safe and effective [16,17,31]. Although our
study was not initially designed to address this issue, our find-
ings in a subgroup analysis support these findings.
By using binary logistic regression, we identified thrombocyto-
penia, hyponatraemia and anaemia to be of decreased signifi-
cance as predictors of need for advanced supportive care. As
with anaemia, low platelets have been identified as markers of
severity and predictors of fatality by other investigators
[2,11,27-30]. In contrast, hyponatraemia in falciparum malaria
is usually mild and not regarded to be an indicator of compli-
Table 3
Complications
Criteria Definition Number of patients (%)
Unrousable coma Glasgow Coma Scale score ≤9; exclude other causes; should persist ≥30 minutes 
after a generalized convulsion
3 (2,5)
Impaired consciousness Mental clouding, rousable 11 (9)
Multiple seizures Three or more convulsions observed within 24 hours 0 (0)
Respiratory distress Acidotic breathing, pulmonary oedema, or acute respiratory distress syndrome, on the 
basis of radiographic densities, hypoxaemia, and positive end-expiratory pressure
4 (3.3)
Circulatory collapse or shock Systolic blood pressure <80 mmHg despite adequate volume repletion 5 (4.1)
Abnormal bleeding Spontaneous bleeding from gums, nose, gastrointestinal tract, or laboratory evidence 
of disseminated intravascular coagulation
4 (3.3)
Jaundice/hyperbilirubinaemia Icteric sclera/buccal mucosa, or serum bilirubin >50 μmol/l (>3 mg/dl) 17 (13.9)
Severe anaemia Heemoglobin concentration <5 g/l, or haematocrit <15% 0 (0)
Hypoglycaemia Whole blood glucose concentration <2.2 mmol/l (<40 mg/dl) 3 (2.5)
Renal failure Serum creatinine >265 μmol/l, oliguria (<400 ml/24 hours) despite adequate 
rehydration
5 (4.1)
Hyperparasitaemia More than 5% parasitized erythrocytes or >250,000 parasites/μl (in nonimmune 
individuals)
13 (10.7)
Acidosis Plasma bicarbonate <15 mmol/l or base excess under -10, or acidaemia (arteria/
capillaryl pH <7.25)
4 (3.3)
Macroscopic haemoglobinuria Dark or red urine; exclude haematuria, haemolysis not secondary to glucose-6-
phosphate dehydrogenase deficiency
ND
The complications are defined according to the World Health Organization classification system [20] (n = 34 patients). ND, not determined
Table 4
Life-threatening complications in 13 patients with imported falciparum malaria
Complication Present on admission (n) Developing during ICU stay (n)
Unrousable coma 0 3
Respiratory distress 2 2
Circulatory collapse or shock 0 5
Abnormal bleeding/disseminated intravascular 
coagulation
40
Hypoglycaemia 0 3
Acidosis 2 2
Renal failure 2 3
Multiple seizures 0 0
Severe anaemia 0 0
ICU, intensive care unit.Critical Care    Vol 12 No 1    Schwake et al.
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cations. In rare cases, however, severe hyponatraemia may
cause cerebral oedema and coma, and thus complicated falci-
parum malaria [31,32]. In view of these findings it is notewor-
thy that factors predicting disease severity vary between study
centres and cannot be generalized for all conditions
[11,29,32-34]. Hence, the presence of thrombocytopenia,
hyponatraemia and/or anaemia at admission should raise par-
ticular concern about secondary complications requiring
advanced supportive care. Their absence, however, does not
exclude fulminate courses of the disease. Also, because of the
retrospective nature of the study, neither plasma lactate at
admission nor time from symptom onset to antimalarial therapy
initiation could be retrieved from the patients' charts. Both
parameters have been shown to be important prognostic fac-
tors in falciparum malaria [35].
An important finding of our study is that the vast majority
(80.3%) of our patients took either no or inappropriate chem-
oprophylaxis. This is comparable to the findings of other stud-
ies and proves once again the need for more effective
prevention strategies, including better patient complicance
[2,36,37].
Our study has limitations that should be mentioned. First, as a
retrospective case review performed in a single centre, it is
subject to several possible biases, namely reporting bias and
selection bias. Hence, because of its retrospective nature, our
evaluation can generate hypothesis but cannot prove causal-
ity. In particular, we cannot definitely exclude the possibility
that the low number of serious complications and the favoura-
ble therapeutic outcomes in our patient group is due to selec-
tion rather than to treatment strategy. Second, other centres
have reported low or no mortality even without early IMC/ICU
treatment [37-39]. Hence, other factors, including rapidity and
accuracy of diagnosis, but also the multidisciplinary nature and
availability of specialists in German tropical medicine depart-
ments (who are usually affilitated to university hospitals),
should also be considered as important determinants of
treatment response. Third, we did not have a control group of
patients treated in accordance with conventional practice.
Table 5
Monitoring and supportive care procedures in all 122 patients
Number of patients (%)
Monitoring and basic supportive care 122 (100)
Continuous monitoring (ECG, oxygen status, blood pressure) 122 (100)
Intravenous fluid and electrolyte replacement 86 (70.5)
Oxygen supply 32 (26.2)
Central venous catheterization 37 (30.3)
Arterial catheterization 9 (7.4)
Advanced supportive care 27 (22.1)
Transfusion of blood products 20 (16.4)
Inotropic drug therapy 5 (4.1)
Noninvasive ventilatory support 4 (3.3)
Invasive ventilation 3 (2.5)
Renal replacement therapy 4 (3.3)
Total parenteral nutrition 12 (9.8)
ECG, electrocardiogram.
Table 6
Predictors of advanced supportive care in multivariate logistic regression analysis
Variable Coefficient Standard error Odds ratio 95% confidence interval P
Haemoglobin (g/dl; mean ± SD) -0.374 0.174 0.688 0.489–0.967 0.031
Platelet count (× 109/l, mean ± SD) -0.032 0.012 0.968 0.946–0.991 0.007
Serum sodium (mmol/l; mean ± SD) -0.213 0.085 0.808 0.685–0.954 0.012
A total of 108 patients were included in this analysis. SD, standard deviation.Available online http://ccforum.com/content/12/1/R22
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However, even in a prospective design, ethical considerations
would probably have prevented us from including one. Finally,
additional treatment costs as well as appropriate treatment
duration in the IMC/ICU remain to be determined. In times of
rationing ICU resources, this question is of particular impor-
tance. In the future, alternatives to our strategy may arise from
the implementation of rapid response systems, including in-
hospital medical emergency teams [40,41].
Conclusion
In summary, this is the first study to show that early monitoring
and treatment in the IMC/ICU is indeed associated with a
favourable therapeutic outcome in patients with imported fal-
ciparum malaria. However, because of methodological limita-
tions we cannot recommend a general change in common
treatment policy.
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